West Pharmaceutical Services Q3 FY26: where the revenue came from and where it went
The whole income statement of West Pharmaceutical Services for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
- Reported
- Oct 29, 2026
Revenue$0.88B
+9% year over year
Gross profit$0.35B
40% margin
Operating profit$0.27B
31% margin
Net profit$0.21B
24% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.88 | 100% | +9% |
| Proprietary products | 0.73 | 83% | +13% |
| West vantage | 0.15 | 17% | |
| Cost of revenue | −0.53 | 60% | |
| Gross profit | 0.35 | 40% margin | +3pp |
| R&D | −0.02 | 2% | +0pp |
| SG&A | −0.06 | 7% | |
| Operating profit | 0.27 | 31% margin | +10pp |
| Other income, net | 0.01 | ||
| Tax | −0.06 | ||
| Net profit | 0.21 | 24% margin | +7pp |
37 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest